Cardio-Renal-Metabolic
Pipeline
About our Cardio-Renal-Metabolic Diseases efforts
Building on our legacy of innovative treatments for a range of cardiovascular, renal and metabolic conditions, our R&D strategy takes a holistic view of the needs of people with metabolic diseases such as diabetes, who often have multiple, related conditions. We are pursuing the next wave of innovative medicines for obesity, kidney and liver diseases – including metabolic dysfunction-associated steatohepatitis (MASH).
Cardio-Renal-Metabolic
Obesity
GLP1/GCGR agonist
Survodutide (BI 456906)
Cardio-Renal-Metabolic
Chronic kidney disease
Aldosterone synthase inhibitor & SGLT2 inhibitor
Vicadrostat (BI 690517) & Empagliflozin
Cardio-Renal-Metabolic
Heart failure with preserved ejection fraction
Aldosterone synthase inhibitor & SGLT2 inhibitor
Vicadrostat (BI 690517) & Empagliflozin
Cardio-Renal-Metabolic
Focal Segmental Glomerulosclerosis
TRPC6 inhibitor
BI 764198
Cardio-Renal-Metabolic
Myocardial infarction
Heart disease modulator
BI 765845
Cardio-Renal-Metabolic
Metabolic Dysfunction-Associated Steatohepatitis
GLP1/GCGR agonist
Survodutide (BI 456906)